INTRODUCTION {#s1}
============

Direct single fields are commonly used in radiotherapy for thoracic and lumbar spinal bone metastases \[[@RRT044C1]\]. It is crucial to define the point to which the dose is prescribed. Variations of the point cause changes in doses for the tumor and organs at risk, particularly for the spinal cord, which may lead to variations in the efficacy and safety of radiotherapy for spinal bone metastases \[[@RRT044C2]\]. According to the guidelines from the International Bone Metastases Consensus Working Party (IBMCWP) updated in 2010, different opinions exist on whether this therapy should be prescribed to the mid-vertebral or anterior vertebral body \[[@RRT044C3]\]. However, to our knowledge, no previous studies have surveyed practice patterns regarding this discrepancy. Therefore, we investigated the current practice patterns in Japan.

MATERIALS AND METHODS {#s2}
=====================

Members of the Japanese Radiation Oncology Study Group (JROSG), all of whom were radiation oncologists, completed an Internet-based survey from December 2010 to January 2011. Respondents were asked to define the point to which the dose is prescribed for a single direct field in a case of spinal bone metastases, in addition to the radiotherapy dose fractionation they would recommend for hypothetical cases describing patients with painful bone metastases \[[@RRT044C4]\]. As a reference for the variability of irradiated dose, we calculated monitor unit ratios for each point at which respondents prescribed radiotherapy compared to cases prescribed for the mid-vertebral body, using 40 simulation CT scans involving patients previously treated for thoraco-lumbar spinal bone metastases.

RESULTS {#s3}
=======

A total of 52 radiation oncologists from 50 institutions (36% of JROSG institutions) responded. Of those, 32 respondents (62%) work at university hospitals or cancer centers, 15 (29%) at public hospitals, and 5 (10%) at private hospitals.

Respondent prescription for radiotherapy for a single direct field for spinal bone metastases varied widely (Table [1](#RRT044TB1){ref-type="table"}). Monitor unit ratios ranged from 0.76--1.10 relative to that prescribed for the mid-vertebral body. Only 21% and 6% of respondents prescribed irradiation to the mid-vertebral body and anterior vertebral body, respectively. A larger proportion of respondents (27%) prescribed irradiation to the spinal cord (center of the spinal canal). Still another group of respondents (27%) stated that they never use a single direct field. Table 1.Points where respondents prescribed radiotherapy for a single direct field for spinal bone metastases (*n* = 52)PointsMonitor Unit ratio^a^Number (%)Anterior vertebral body1.103 (6%)Mid-vertebral body1 (referent)11 (21%)Posterior vertebral body0.922 (4%)Spinal cord (center of the spinal canal)0.8914 (27%)3-cm depth0.811 (2%)6-cm depth0.944 (8%)Maximum dose point0.761 (2%)Center of the gross tumor volume0.941 (2%)Adjust the point, considering dose distribution1 (2%)Never use a single direct field14 (27%)[^1]

DISCUSSION {#s4}
==========

Large variations were found amongst respondents prescribing radiotherapy for a single direct field. These variations cause changes in doses for the tumor and organs at risk, which may lead to variations in the efficacy and safety \[[@RRT044C2]\]. Furthermore, the variations may make it difficult to clarify the tolerance dose of the spinal cord in cases of re-irradiation. While recurrent pain in spinal bones can be successfully alleviated with external beam radiotherapy re-treatment, optimal dosage and fractionation are still under investigation \[[@RRT044C5]\]. Nieder *et al*. collected data from 40 individual patients who received re-irradiation of the spinal cord, published in eight different reports, and mentioned that the risk of radiation-induced myelopathy appears to be small after cumulative doses of ≤135.5 Gy~2~ when the interval is not less than 6 months and the dose of each course is ≤98 Gy~2~ \[[@RRT044C6]\]. However, the cumulative dose was calculated from prescribed doses without the absolute correctness of the doses to the spinal cord.

According to the guideline from the IBMCWP, updated in 2010, opinion was split between prescribing to the mid-vertebral body or anterior vertebral body \[[@RRT044C3]\]. However, only 21 and 6% of respondents prescribed irradiation to the mid-vertebral body and anterior vertebral body, respectively. Japanese radiation oncologists may be concerned that prescribing irradiation to the mid-vertebral body or anterior vertebral body may cause too high a dose to the spinal cord.

A larger proportion of respondents prescribed irradiation to the spinal canal (center of the spinal canal). A recent large multi-institutional randomized controlled trial (RCT) prescribed irradiation to the posterior edge of the vertebral body \[[@RRT044C7]\] (Table [2](#RRT044TB2){ref-type="table"}). The monitor units we calculated were similar between the prescription to the posterior vertebral body and to the spinal cord. Furthermore, some RCTs prescribed to a 5-cm depth, which was probably close to the spinal canal. Therefore, it seems to be reasonable to prescribe irradiation to the spinal canal if we do not consider the guideline of the IBMCWP \[[@RRT044C1]\]. Table 2.The point to which single direct irradiation was prescribed for spinal bone metastases in large multi-institutional randomized controlled trialsAuthorCountryYear publishedTreatment armsPointPrice, *et al.* \[[@RRT044C8]\]UK19868 Gy single vs 30 Gy/10 fractions5-cm depthGaze, *et al.* \[[@RRT044C9]\]UK199710 Gy single vs 22.5 Gy/5 fractionsappropriate depthNielsen, *et al.* \[[@RRT044C10]\]Denmark and UK19988 Gy single vs 20 Gy/5 fractionsmaximum absorbed doseBone Pain Trial Working Party \[[@RRT044C11]\]UK and New Zealand19998 Gy single vs 20 Gy/5 fractions or 30 Gy/10 fractions5-cm depthSteenland, *et al.* \[[@RRT044C12]\]The Netherlands19998 Gy single vs 24 Gy/6 fractionsno guidelinesHartsell, *et al.* \[[@RRT044C13]\]US20058 Gy single vs 30 Gy/10 fractionsmiddle of the vertebral bodyRoos, *et al.* \[[@RRT044C14]\]Australia, New Zealand, and UK20058 Gy single vs 20 Gy/5 fractions5-cm depthKaasa, *et al.* \[[@RRT044C7]\]Norway and Sweden20068 Gy single vs 30 Gy/10 fractionsposterior edge of the vertebral corpora

Although the efficacy and safety of radiotherapy using a single direct field for spinal bone metastases have been proven through numerous clinical trials for both single- and multi-fraction radiotherapy \[7--15\], a large number of respondents stated that they never use a single direct field for spinal bone metastases. Those who never use a single direct field may prefer to use parallel opposing fields or highly conformal radiotherapy. Parallel opposed fields give a more homogenous dose distribution, which can avoid overdosing the spinal cord or underdosing the tumor. Stereotactic body radiotherapy (SBRT) is a technology that delivers high doses to spinal metastases with a steep dose gradient, which might allow superior sparing of the adjacent organs at risk, including the spinal cord. However, the efficacy and safety of SBRT have not been fully evaluated yet, and the ASTRO evidence-based guideline published in 2011 strongly suggests that SBRT should only be used within clinical trials \[[@RRT044C16]\].

Our study has certain limitations. Due to the relatively low response rate (36%) and small absolute sample size (*n* = 52), our results might not accurately represent the practice of radiation oncologists in Japan. Furthermore, those willing to participate might have been more knowledgeable than those unwilling to participate.

In conclusion, the point to which irradiation dosages are prescribed varies widely for a single direct field in cases of spinal bone metastases. This variation may lead some radiation oncologists to misunderstand the tolerance dosage of the spinal cord, especially in cases of re-irradiation. Thus, careful consideration is required before any prescriptions are made.
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[^1]: ^a^Forty simulation CT scans previously treated for thoraco-lumbar spinal bone metastases were used for the calculation.
